| Browse All

Assembly Biosciences, Inc. (ASMB)

Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
29.24 USD -0.08 (-0.273%) ⇩ (April 17, 2026, 4 p.m. EDT)
After hours: 29.24

Short-term: ★★★★☆ | Long-term: ★★★★☆ | Dividends: ☆☆☆☆☆
Hot Take | April 18, 2026, 10:28 p.m. EDT

ASMB presents a compelling 'bottom-fish' opportunity in a biotech that has recently received a catalyst boost (HSV drug results) but is trading well below analyst consensus targets (Range: 40-62, Mean: 48.75). While the company remains unprofitable with negative margins, the balance sheet is incredibly strong with minimal debt and a current ratio of 5.2, implying a very low risk of bankruptcy in the near term. The technicals show a bounce from the 52-week low, and options market positioning is bullish, pricing in continued recovery to the upside.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoARIMA ✓0.046655
AutoETS0.047145
MSTL0.048222
AutoTheta0.103228

Forecast horizon: 45 days | Selected: AutoARIMA

Forecast Reliability
Score 72%
H-stat 1.26
Ljung-Box p 0.000
Jarque-Bera p 0.088
Excess Kurtosis -0.49
Attribute Value
Sector Healthcare
Debt to Equity Ratio 1.271
Revenue per Share 6.449
Market Cap 463,825,504
Forward P/E -12.66
Beta 1.16
Profit Margins -8.47%
Website https://www.assemblybio.com

As of April 18, 2026, 10:28 p.m. EDT: Options flow shows a significant bullish skew. Call Open Interest (OI) is heavily concentrated in OTM strikes for June (40 strike) and September (45 strike), indicating speculator positioning for upside beyond the current price. The largest net OI gain is in OTM calls (June 40 strike and Sept 45 strike). Conversely, PUT OI is negligible and concentrated deep ITM, suggesting minimal hedging demand. Open Interest has effectively vanished for near-term OTM calls (May 15 25/30 strikes), meaning the current signal is driven by new entry into longer-dated upside structures. Overall momentum is clearly directional to the upside.


Info Dump

Attribute Value
52 Week Change 1.9416499
Address1 Two Tower Place
Address2 7th Floor
All Time High 1,260.0
All Time Low 7.68
Ask 29.85
Ask Size 2
Audit Risk 6
Average Daily Volume10 Day 124,210
Average Daily Volume3 Month 98,717
Average Volume 98,717
Average Volume10Days 124,210
Beta 1.158
Bid 28.64
Bid Size 2
Board Risk 3
Book Value 13.04
City South San Francisco
Compensation As Of Epoch Date 1,735,603,200
Compensation Risk 6
Country United States
Crypto Tradeable 0
Currency USD
Current Price 29.24
Current Ratio 5.218
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 30.19
Day Low 28.8
Debt To Equity 1.271
Display Name Assembly Biosciences
Earnings Timestamp End 1,754,942,400
Earnings Timestamp Start 1,754,510,400
Ebitda -11,989,000
Ebitda Margins -0.16582
Enterprise To Ebitda -18.212
Enterprise To Revenue 3.02
Enterprise Value 218,347,488
Eps Current Year -1.22667
Eps Forward -2.31
Eps Trailing Twelve Months -0.55
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 28.4502
Fifty Day Average Change 0.78980064
Fifty Day Average Change Percent 0.027760813
Fifty Two Week Change Percent 194.165
Fifty Two Week High 39.71
Fifty Two Week High Change -10.469999
Fifty Two Week High Change Percent -0.26366153
Fifty Two Week Low 9.82
Fifty Two Week Low Change 19.42
Fifty Two Week Low Change Percent 1.9775968
Fifty Two Week Range 9.82 - 39.71
Financial Currency USD
First Trade Date Milliseconds 1,292,596,200,000
Float Shares 7,490,528
Forward Eps -2.31
Forward P E -12.658009
Free Cashflow -4,983,750
Full Exchange Name NasdaqGS
Full Time Employees 73
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,775,001,600
Gross Margins 0.103590004
Gross Profits 7,490,000
Has Pre Post Market Data 1
Held Percent Insiders 0.32206002
Held Percent Institutions 0.59943
Implied Shares Outstanding 15,862,705
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,707,696,000
Last Split Factor 1:12
Long Business Summary Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Long Name Assembly Biosciences, Inc.
Market us_market
Market Cap 463,825,504
Market State CLOSED
Max Age 86,400
Message Board Id finmb_99715344
Most Recent Quarter 1,767,139,200
Net Income To Common -6,122,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 463,825,494
Number Of Analyst Opinions 4
Open 29.91
Operating Cashflow -41,093,000
Operating Margins 0.4662
Overall Risk 3
Payout Ratio 0.0
Phone 833 509 4583
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 29.24
Post Market Time 1,776,456,604
Previous Close 29.32
Price Eps Current Year -23.836891
Price Hint 2
Price To Book 2.2423313
Price To Sales Trailing12 Months 6.4150243
Profit Margins -0.08467
Quick Ratio 5.137
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.0799999
Regular Market Change Percent -0.272851
Regular Market Day High 30.19
Regular Market Day Low 28.8
Regular Market Day Range 28.8 - 30.19
Regular Market Open 29.91
Regular Market Previous Close 29.32
Regular Market Price 29.24
Regular Market Time 1,776,456,001
Regular Market Volume 229,833
Return On Assets -0.0402
Return On Equity -0.05099
Revenue Growth 4.773
Revenue Per Share 6.449
Sand P52 Week Change 0.38150132
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 2
Shares Outstanding 15,862,705
Shares Percent Shares Out 0.096599996
Shares Short 1,533,102
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 1,479,082
Short Name Assembly Biosciences, Inc.
Short Percent Of Float 0.113199994
Short Ratio 20.26
Source Interval 15
State CA
Symbol ASMB
Target High Price 62.0
Target Low Price 40.0
Target Mean Price 48.75
Target Median Price 46.5
Total Cash 248,106,000
Total Cash Per Share 15.641
Total Debt 2,628,000
Total Revenue 72,303,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -0.55
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 27.69335
Two Hundred Day Average Change 1.5466499
Two Hundred Day Average Change Percent 0.055849146
Type Disp Equity
Volume 229,833
Website https://www.assemblybio.com
Zip 94,080